Shabir Madhi to Cost-Benefit Analysis
This is a "connection" page, showing publications Shabir Madhi has written about Cost-Benefit Analysis.
Connection Strength
0,304
-
The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLoS One. 2020; 15(1):e0227945.
Score: 0,151
-
Quantifying How Different Clinical Presentations, Levels of Severity, and Healthcare Attendance Shape the Burden of Influenza-associated Illness: A Modeling Study From South Africa. Clin Infect Dis. 2019 08 30; 69(6):1036-1048.
Score: 0,037
-
The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine. 2019 05 27; 37(24):3190-3198.
Score: 0,036
-
Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa. Vaccine. 2019 01 03; 37(1):25-33.
Score: 0,035
-
Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine. 2014 Apr 07; 32(17):1954-63.
Score: 0,025
-
An evaluation of emerging vaccines for childhood pneumococcal pneumonia. BMC Public Health. 2011 Apr 13; 11 Suppl 3:S26.
Score: 0,021